News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sanofi-Aventis (France) (SASY.PA) Rejects Novo Nordisk A/S (NVO) Suit, New Drug May Face Delay


10/19/2005 5:12:41 PM

PARIS, Sept 23 (Reuters) - Sanofi-Aventis SA (SASY.PA: Quote, Profile, Research) said on Friday it would defend itself against a patent lawsuit by Denmark's Novo Nordisk (NOVOb.CO: Quote, Profile, Research), which analysts said could delay the U.S. launch of Sanofi's new insulin treatment Apidra.

Read at Reuters

comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES